Barinthus Biotherapeutics plc. 8-K

What Happened

• Barinthus Biotherapeutics plc (ticker: BRNS) filed a Form 8-K on March 13, 2026 to report its results of operations and financial condition for the year ended December 31, 2025. The company furnished a press release with the results and overview as Exhibit 99.1 to the filing. On the same day it also updated its corporate presentation for investor and analyst meetings, furnished as Exhibit 99.2.

Key Details

• Filing date: March 13, 2026; reporting period: year ended December 31, 2025.
• Press release with the financial results provided as Exhibit 99.1; updated corporate deck provided as Exhibit 99.2.
• The company stated it undertakes no obligation to update or amend the presentation.
• The Form 8-K was signed by CEO William Enright.

Why It Matters

• This filing gives investors the company’s official 2025 financial results and an updated investor presentation — the primary sources to assess recent financial performance, trends in earnings/revenue, and management’s messaging.
• The updated deck and press release are the materials analysts and shareholders will use to evaluate results and any near-term strategy changes; the company’s statement that it won’t update the presentation means investors should rely on the press release and reach out to the company for any subsequent clarifications.